This experiment addresses a critical evidence gap: while iron accumulation in the substantia nigra is a well-documented pathological feature of Parkinson's disease (PD), the role of astrocytic ferritin iron metabolism in disease progression remains poorly understood. Astrocytes are the primary iron-storing cells in the brain and play a crucial role in neuronal iron homeostasis, yet therapeutic targeting of astrocyte iron metabolism has not been systematically explored.
This experiment will characterize astrocyte ferritin dysfunction in PD and test whether enhancing astrocytic iron export or reducing iron storage can provide neuroprotection.
Primary Hypothesis: Dysfunctional astrocytic ferritin iron metabolism contributes to dopaminergic neuron death in PD, and pharmacological enhancement of astrocytic iron export (via ferroportin) or reduction of astrocytic iron storage (via ferritin modulation) will reduce oxidative stress and provide neuroprotection.
Secondary Hypotheses:
- Astrocytes from PD patients show impaired ferroportin expression and increased ferritin accumulation compared to healthy controls
- Iron released from dysfunctional astrocytes promotes alpha-synuclein aggregation
- Combination of iron metabolism modulation with existing therapies (e.g., L-DOPA, MAO-B inhibitors) will show synergistic effects
- Compare ferritin and ferroportin expression in astrocytes from PD patient iPSCs vs. healthy controls
- Measure intracellular iron accumulation using live-cell iron sensors
- Quantify iron release rates under various conditions
- Test whether iron released from astrocytes promotes alpha-synuclein nucleation
- Use seeded aggregation assays with astrocyte-conditioned media
- Determine iron species responsible (Fe2+ vs. Fe3+)
- Screen 300+ compounds for ability to enhance ferroportin expression
- Screen for ferritin degradation enhancers
- Test in astrocyte-neuron co-culture systems
- Test top 2 lead compounds in MPTP mouse model of PD
- Measure: dopaminergic neuron survival, motor behavior, iron levels, alpha-synuclein pathology
- Establish PK/PD relationships
- iPSC-derived astrocytes from 5 PD patients (LRRK2 G2019S, GBA1, idiopathic)
- iPSC-derived astrocytes from 5 age-matched healthy controls
- Primary human astrocytes (commercially available)
- Western blot for ferritin (H and L subunits), ferroportin, transferrin receptor
- Immunofluorescence for cellular iron localization (Perls staining)
- Live-cell imaging with FeR reporter (calcium-based iron sensor)
- Iron release assays using 55Fe radiolabeled transferrin
- Primary antibodies: Ferritin (Abcam ab69090), Ferroportin (Novus Biologicals NBP1-21502)
- iPSC lines: WiCell lines, authenticated
- Iron sensors: FeR-Green1 (Thermo Fisher)
- Collect conditioned media from PD vs. control astrocytes
- Add to alpha-synuclein seed amplification assays (RT-QuIC)
- Test with/without iron chelation (deferoxamine, clioquinol)
- RT-QuIC for alpha-synuclein aggregation kinetics
- Thioflavin T fluorescence assays
- Western blot for alpha-synuclein phosphorylation (pS129)
- FDA-approved drug library (200 compounds)
- Known iron chelators (50 compounds)
- Ferroportin activators (50 compounds)
- Primary screen: Ferroportin promoter-luciferase reporter in astrocytes
- Secondary: Iron release assay using 55Fe
- Tertiary: Astrocyte-neuron co-culture neuroprotection assay
- Test top 20 hits in astrocyte-neuron co-cultures
- Measure: neuronal viability, iron levels, oxidative stress markers
- C57BL/6 mice, MPTP-induced PD model
- Treatment groups: Vehicle, Lead compound 1, Lead compound 2, Positive control (deferoxamine)
- Stereological counting of tyrosine hydroxylase (TH)+ neurons in substantia nigra
- Rotarod and cylinder test for motor function
- Perls staining for brain iron levels
- pS129 alpha-synuclein immunohistochemistry
- Biochemical: iron, ferritin, ferroportin in brain tissue
¶ Reagents and Costs
- Principal Investigator (20% effort): $60,000
- Postdoctoral Researcher (2): $180,000
- Research Technician: $90,000
- Graduate Student: $60,000
- Research Coordinator: $90,000
- Live-cell imaging system (IncuCyte): $45,000
- Plate reader (fluorescence/luminescence): $25,000
- Cryostat: $15,000
- iPSC lines and differentiation kits: $45,000
- Antibodies: $35,000
- Compound libraries: $40,000
- Iron sensors and tracers: $25,000
- Animal costs (mice, housing): $35,000
- Reagents for biochemistry: $15,000
- Animal facility costs: $60,000
- Bioinformatics/analysis: $30,000
- Publication costs: $15,000
- Contingency (15%): $35,000
- Dr. Michael Aschner (Albert Einstein College of Medicine) - Brain iron metabolism
- Dr. James Connor (Penn State) - Ferritin and iron in neurodegeneration
- Dr. Rajesh Ambasudhan (UT Southwestern) - Astrocyte biology
- Dr. Birgit Lang (University of Tuebingen) - LRRK2 and iron
- Dr. Kalyan J. Outeiro (University of Exeter) - Alpha-synuclein and iron
- Dr. Ashley Zhang (UCLA) - iPSC models of PD
- Dr. Stefano L. Sensi (University of Chieti) - Iron chelation therapy
- Dr. Peng Lei (Shanghai Jiao Tong) - Ferroportin biology
- Dr. Masahiko Takada (Tokyo Metropolitan Institute) - Non-human primate models
- Dr. Suman Dutta (All India Institute of Medical Sciences) - Population genetics of iron-related genes
- Dr. Claudia Duran (University of Sao Paulo) - Latin American PD cohorts
- Phase 1 (Months 1-6): Astrocyte characterization - $180,000
- Phase 2 (Months 4-10): Iron-aggregation studies - $150,000
- Phase 3 (Months 6-14): Drug screening - $220,000
- Phase 4 (Months 12-24): In vivo validation - $250,000
- Analysis (Months 22-26): Data integration - $50,000
- Contingency: $50,000
Total: 26 months, $900,000
- Directly addresses iron accumulation, a hallmark of PD pathogenesis
- Bridges astrocyte biology with neurodegeneration
- Potential to identify novel therapeutic targets
- iPSC-derived astrocyte models are well-established
- Iron assays are routine
- In vivo validation is standard
- First systematic study of astrocytic ferritin in PD
- Ferroportin as therapeutic target is underexplored
- Iron-alpha-synuclein link in astrocyte context is novel
- Iron dysregulation is a core PD pathological feature
- Addresses unmet need for disease-modifying therapies
- Potential for combination with existing treatments
- Primarily PD-focused
- May have implications for other neurodegenerative diseases with iron dysregulation
- Findings could inform iron metabolism in aging
- Moderate cost for comprehensive study
- Drug repurposing approach reduces development costs
- In vivo validation adds cost but is necessary
- 26 months is reasonable for this scope
- Some phases can run in parallel
- In vivo validation is time-intensive but essential
- Strong preclinical evidence for iron's role in PD
- Astrocyte involvement is emerging area
- Some gaps in understanding astrocyte-neuron iron transfer
- Tests whether astrocyte iron dysregulation is cause or consequence
- Determines therapeutic potential of iron modulation
- Clarifies iron-alpha-synuclein relationship
- Drug repurposing for iron metabolism is feasible
- Ferroportin modulators already in development for other conditions
- Clear path to IND-enabling studies if leads identified
Total Raw Score: 82/100
Weighted Score: 82 × 1.4 = 114.8/140